JNCI Journal of the National Cancer Institute最新文献

{"title":"RE: Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy.","authors":"Amed Trak, Dilara Turan Gökçe","doi":"10.1093/jnci/djaf261","DOIUrl":"https://doi.org/10.1093/jnci/djaf261","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing high-quality cancer survivorship care in primary care: future directions for policy and research.","authors":"Julien A M Vos, Nicole L Stout, Larissa Nekhlyudov","doi":"10.1093/jnci/djaf259","DOIUrl":"https://doi.org/10.1093/jnci/djaf259","url":null,"abstract":"<p><p>Nearly 20 million people in the U.S. are living with and beyond a cancer diagnosis, many of whom survive for decades after treatment. As this population continues to grow and age, primary care (PC) plays an increasingly important role in managing long-term and late effects of treatment. However, efforts to improve survivorship care (SC) delivery in PC have only recently gained attention. With more survivors relying on their primary care clinicians (PCCs), there is a clear need to strengthen the implementation of high-quality SC in PC settings. In this commentary, we explore how high-quality SC can be implemented in PC, using the implementation plan outlined in the National Academies of Sciences, Engineering, and Medicine (NASEM) report Implementing High-Quality Primary Care: Rebuilding the Foundation of Health Care. We describe the evidence on PCCs' roles across the cancer care continuum and map the evidence to the NASEM report's five implementation objectives: payment, access, workforce, digital health, and accountability. Through this work, we identify future directions for policy and research to ensure that PC can serve as a \"common good\" for all cancer survivors.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.","authors":"Daniele Presti, Antonio Di Meglio, Julie Havas, Martina Pagliuca, Bianca Cheaib, Anne-Laure Martin, Catherine Gaudin, Christelle Jouannaud, Marion Fournier, Anne Kieffer, Mario Campone, Florence Lerebours, Thierry Petit, Sandrine Boyault, Aurelie Bertaut, Olivier Tredan, Francois Cherifi, Marie Lange, Caroline Pradon, Ines Vaz-Luis, Florence Joly","doi":"10.1093/jnci/djaf256","DOIUrl":"https://doi.org/10.1093/jnci/djaf256","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) survivors receiving adjuvant treatments often report clinically relevant cancer-related cognitive complaints (CRCC), which have a significant impact on quality of life. We aimed to develop a comprehensive model of prediction of CRCC, including clinical and serum inflammatory protein data.</p><p><strong>Methods: </strong>We included 9575 stage I-III BC patients from the CANTO cohort (NCT01993498). Data were collected at diagnosis, 2(year-2) and 4(year-4) years post-diagnosis. Outcome of interest was CRCC (cognitive dimension of the EORTC QLQ-C30 questionnaire, score < 75/100) at year-2 and year-4. Serum inflammatory markers (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFNg, IL-1, IL1Ra, TNF-a, CRP) were available in a subset of patients with hormone-receptor-positive BC. Multivariable logistic regression models assessed associations of baseline clinical and inflammatory variables with CRCC.</p><p><strong>Results: </strong>Rates of CRCC were 31% (diagnosis), 39% (year-2), and 37% (year-4). Baseline validated predictors of CRCC reported at year-2 were chemotherapy, pre-treatment CRCC, pain, and fatigue; predictors of CRCC reported at year-4 were pre-treatment CRCC, pain, and anxiety. Other clinically relevant factors associated with CRCC at both timepoints during model development were pre-treatment insomnia, receipt of endocrine therapy, and younger age/premenopausal status. No significant associations were observed between inflammatory markers and CRCC.</p><p><strong>Conclusions: </strong>Approximately one-in-three BC survivors in this cohort reported CRCC at diagnosis, with this rate being stable until year-4 after diagnosis. Pre-treatment symptom burden and chemotherapy were validated as risk factors for long term CRCC. No associations between inflammatory markers and self-reported CRCC emerged from this study.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma.","authors":"Ammar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, Omar Mahmud, Iris W J M van Goor, Joseph R Habib, Paul Andel, Brady A Campbell, Thijs J Schouten, Fabio Bagante, Nabiha A Mughal, Thomas F Stoop, Kelly J Lafaro, Richard A Burkhart, William R Burns, D Brock Hewitt, Greg D Sacks, Hjalmar C van Santvoort, Marcel den Dulk, Freek Daams, J Sven D Mieog, Martijn W J Stommel, Gijs A Patijn, Ignace de Hingh, Sebastiaan Festen, Maarten W Nijkamp, Joost M Klaase, Daan J Lips, Jan H Wijsman, Erwin van der Harst, Eric Manusama, Casper H J van Eijck, Bas Groot Koerkamp, Geert Kazemier, Olivier R Busch, I Quintus Molenaar, Lois A Daamen, Marc G Besselink, Jin He, Christopher L Wolfgang","doi":"10.1093/jnci/djaf196","DOIUrl":"https://doi.org/10.1093/jnci/djaf196","url":null,"abstract":"<p><strong>Background: </strong>Prognostic factors in resected pancreatic ductal adenocarcinoma (PDAC) have been determined under the assumption that hazard ratios (HRs) remain static. However, PDAC is a dynamic disease with evolving conditional survival. The aim of this study was to determine if the impact of prognostic factors in PDAC is time-varying.</p><p><strong>Methods: </strong>This was a multicenter, retrospective cohort study of the prospectively maintained Dutch Pancreatic Cancer Recurrence Database and New York University and Johns Hopkins Hospital Institutional Databases. Patients with complete macroscopic resection of histopathologically proven PDAC between 2014 and 2019 and available follow-up data were included. The time-varying impact of prognostic factors identified by univariable cox-regression was modelled using Aalen's Additive Regression Models (Aalen's models) and visualized as plots of cumulative hazard.</p><p><strong>Results: </strong>3104 patients were included, of whom 938 (30.2%) received neoadjuvant therapy (NAT) while the rest underwent upfront surgery (US). 201 (6.5%) patients achieved observed long-term survival (>5 years). Aalen's models showed that lymphovascular invasion, perineural invasion, and nodal disease were prognostic up to 2 years post-operatively. At varying points thereafter, these variables lost their impact in the NAT but not US patients. Similarly, during the 4th year of follow-up, American Society of Anesthesiology scores became impactful in the NAT but not in the US patients.</p><p><strong>Interpretation: </strong>The impact of prognostic factors in resected PDAC across NAT and US patients is time-varying. Our results suggest that aggressive disease drives early mortality but, after NAT, tumor-biological factors lose prognostic importance to frailty and comorbidities over time.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.","authors":"Taha Koray Sahin, Deniz Can Guven, Sercan Aksoy","doi":"10.1093/jnci/djaf254","DOIUrl":"10.1093/jnci/djaf254","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Sahin, Guven and Aksoy.","authors":"Edoardo Botteri, Fabio Conforti, Erica K Sloan, Aeson Chang","doi":"10.1093/jnci/djaf255","DOIUrl":"10.1093/jnci/djaf255","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women.","authors":"Gokhan Koker, Gulhan Ozcelik","doi":"10.1093/jnci/djaf252","DOIUrl":"10.1093/jnci/djaf252","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Koker and Ozcelik.","authors":"Jinhee Hur, Xinyi Li, Edward Giovannucci","doi":"10.1093/jnci/djaf253","DOIUrl":"10.1093/jnci/djaf253","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in uterine cancer incidence and mortality: insights from a natural history model.","authors":"William D Hazelton, Matthew Prest, Ling Chen, Kevin Rouse, Elena B Elkin, Jennifer S Ferris, Xiao Xu, Nina A Bickell, Chung Yin Kong, Stephanie Blank, Eric J Feuer, Goli Samimi, Brandy M Heckman-Stoddard, Tracy M Layne, Jason D Wright, Evan R Myers, Laura J Havrilesky","doi":"10.1093/jnci/djaf135","DOIUrl":"10.1093/jnci/djaf135","url":null,"abstract":"<p><strong>Background: </strong>Uterine cancer incidence and mortality are increasing, with concomitant disparities in outcomes between racial groups. Natural history modeling can evaluate risk factors, predict future trends, and simulate approaches to reducing mortality and disparities.</p><p><strong>Methods: </strong>We designed a natural history model of uterine cancer using a multistage clonal expansion design. The model is informed by National Health and Nutrition Examination Survey, National Health Examination Survey, age, time period, birth cohort, and birth certificate data on reproductive histories and body mass index (BMI). We fit and calibrated the model to Surveillance, Epidemiology, and End Results data by race and ethnicity as well as histologic subgroup. We projected future incidence and estimated the degree of contribution of BMI, reproductive history, and competing hysterectomy to excess uterine cancer incidence.</p><p><strong>Results: </strong>The model accurately replicated Surveillance, Epidemiology, and End Results incidence for endometrioid, nonendometrioid, and sarcoma subgroups for non-Hispanic Black and non-Hispanic White patients. For endometrioid, nonendometrioid, and sarcomas, BMI-attributable risks are greater for non-Hispanic White than for non-Hispanic Black patients; reproductive history-attributable risks are greater for non-Hispanic Black patients. Between 2018 and 2050, endometrioid incidence is projected to rise by 64.9% in non-Hispanic Black individuals and17.5% in non-Hispanic White individuals; the projected rise for the nonendometrioid subgroup is 41.4% in non-Hispanic Black individuals and 22.5% in non-Hispanic White individuals; the sarcoma incidence projected increase is 36% in non-Hispanic Black individuals and 29.2% in non-Hispanic White individuals.</p><p><strong>Conclusions: </strong>Uterine cancer risk is substantially explained by reproductive history and BMI, with differences observed between non-Hispanic Black and non-Hispanic White individuals and future projections indicating perpetuation of disparities. Lower rates of hysterectomy and rising obesity rates will likely contribute to continued increases in uterine cancer incidence.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1891-1903"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Saidi and Jones.","authors":"Tim Palmer, Kimberley Kavanagh, Kate Cuschieri, Ross Cameron, Catriona Graham, Allan Wilson, Kirsty Roy","doi":"10.1093/jnci/djaf131","DOIUrl":"10.1093/jnci/djaf131","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1944-1945"},"PeriodicalIF":7.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}